[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Browse CD38

Summary
SymbolCD38
NameCD38 molecule
Aliases ADP-ribosyl cyclase 1; CD38 antigen (p45); ADPRC 1; ADPRC1; 2'-phospho-ADP-ribosyl cyclase; 2'-phospho-cycli ......
Chromosomal Location4p15.32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Membrane; Single-pass type II membrane protein.
Domain PF02267 ADP-ribosyl cyclase
Function

Synthesizes the second messagers cyclic ADP-ribose and nicotinate-adenine dinucleotide phosphate, the former a second messenger for glucose-induced insulin secretion. Also has cADPr hydrolase activity. Also moonlights as a receptor in cells of the immune system.

> Gene Ontology
 
Biological Process GO:0001101 response to acid chemical
GO:0001558 regulation of cell growth
GO:0001666 response to hypoxia
GO:0001894 tissue homeostasis
GO:0002429 immune response-activating cell surface receptor signaling pathway
GO:0002694 regulation of leukocyte activation
GO:0002696 positive regulation of leukocyte activation
GO:0002757 immune response-activating signal transduction
GO:0002764 immune response-regulating signaling pathway
GO:0002768 immune response-regulating cell surface receptor signaling pathway
GO:0002790 peptide secretion
GO:0002791 regulation of peptide secretion
GO:0002793 positive regulation of peptide secretion
GO:0003013 circulatory system process
GO:0003018 vascular process in circulatory system
GO:0006874 cellular calcium ion homeostasis
GO:0006875 cellular metal ion homeostasis
GO:0006979 response to oxidative stress
GO:0007204 positive regulation of cytosolic calcium ion concentration
GO:0007565 female pregnancy
GO:0008015 blood circulation
GO:0009306 protein secretion
GO:0009914 hormone transport
GO:0010817 regulation of hormone levels
GO:0015833 peptide transport
GO:0016049 cell growth
GO:0019229 regulation of vasoconstriction
GO:0023061 signal release
GO:0030072 peptide hormone secretion
GO:0030073 insulin secretion
GO:0030307 positive regulation of cell growth
GO:0030888 regulation of B cell proliferation
GO:0030890 positive regulation of B cell proliferation
GO:0032024 positive regulation of insulin secretion
GO:0032355 response to estradiol
GO:0032526 response to retinoic acid
GO:0032570 response to progesterone
GO:0032844 regulation of homeostatic process
GO:0032845 negative regulation of homeostatic process
GO:0032943 mononuclear cell proliferation
GO:0032944 regulation of mononuclear cell proliferation
GO:0032946 positive regulation of mononuclear cell proliferation
GO:0033194 response to hydroperoxide
GO:0034103 regulation of tissue remodeling
GO:0034104 negative regulation of tissue remodeling
GO:0035150 regulation of tube size
GO:0036293 response to decreased oxygen levels
GO:0042100 B cell proliferation
GO:0042113 B cell activation
GO:0042310 vasoconstriction
GO:0042493 response to drug
GO:0042886 amide transport
GO:0044057 regulation of system process
GO:0044706 multi-multicellular organism process
GO:0045124 regulation of bone resorption
GO:0045453 bone resorption
GO:0045779 negative regulation of bone resorption
GO:0045907 positive regulation of vasoconstriction
GO:0045927 positive regulation of growth
GO:0046651 lymphocyte proliferation
GO:0046849 bone remodeling
GO:0046850 regulation of bone remodeling
GO:0046851 negative regulation of bone remodeling
GO:0046879 hormone secretion
GO:0046883 regulation of hormone secretion
GO:0046887 positive regulation of hormone secretion
GO:0048167 regulation of synaptic plasticity
GO:0048545 response to steroid hormone
GO:0048771 tissue remodeling
GO:0048871 multicellular organismal homeostasis
GO:0050670 regulation of lymphocyte proliferation
GO:0050671 positive regulation of lymphocyte proliferation
GO:0050708 regulation of protein secretion
GO:0050714 positive regulation of protein secretion
GO:0050796 regulation of insulin secretion
GO:0050804 modulation of synaptic transmission
GO:0050805 negative regulation of synaptic transmission
GO:0050851 antigen receptor-mediated signaling pathway
GO:0050853 B cell receptor signaling pathway
GO:0050864 regulation of B cell activation
GO:0050865 regulation of cell activation
GO:0050867 positive regulation of cell activation
GO:0050871 positive regulation of B cell activation
GO:0050880 regulation of blood vessel size
GO:0051047 positive regulation of secretion
GO:0051222 positive regulation of protein transport
GO:0051249 regulation of lymphocyte activation
GO:0051251 positive regulation of lymphocyte activation
GO:0051480 regulation of cytosolic calcium ion concentration
GO:0055074 calcium ion homeostasis
GO:0060249 anatomical structure homeostasis
GO:0060292 long term synaptic depression
GO:0070482 response to oxygen levels
GO:0070555 response to interleukin-1
GO:0070661 leukocyte proliferation
GO:0070663 regulation of leukocyte proliferation
GO:0070665 positive regulation of leukocyte proliferation
GO:0072503 cellular divalent inorganic cation homeostasis
GO:0072507 divalent inorganic cation homeostasis
GO:0090066 regulation of anatomical structure size
GO:0090087 regulation of peptide transport
GO:0090276 regulation of peptide hormone secretion
GO:0090277 positive regulation of peptide hormone secretion
GO:1901654 response to ketone
GO:1903522 regulation of blood circulation
GO:1903524 positive regulation of blood circulation
GO:1903532 positive regulation of secretion by cell
GO:1904951 positive regulation of establishment of protein localization
Molecular Function GO:0003953 NAD+ nucleosidase activity
GO:0016798 hydrolase activity, acting on glycosyl bonds
GO:0016799 hydrolase activity, hydrolyzing N-glycosyl compounds
GO:0016829 lyase activity
GO:0016849 phosphorus-oxygen lyase activity
GO:0050135 NAD(P)+ nucleosidase activity
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG hsa04020 Calcium signaling pathway
hsa04640 Hematopoietic cell lineage
hsa04921 Oxytocin signaling pathway
hsa04970 Salivary secretion
hsa04972 Pancreatic secretion
hsa00760 Nicotinate and nicotinamide metabolism
hsa01100 Metabolic pathways
Reactome R-HSA-1430728: Metabolism
R-HSA-196854: Metabolism of vitamins and cofactors
R-HSA-196849: Metabolism of water-soluble vitamins and cofactors
R-HSA-196807: Nicotinate metabolism
Summary
SymbolCD38
NameCD38 molecule
Aliases ADP-ribosyl cyclase 1; CD38 antigen (p45); ADPRC 1; ADPRC1; 2'-phospho-ADP-ribosyl cyclase; 2'-phospho-cycli ......
Chromosomal Location4p15.32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between CD38 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between CD38 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
28249894Plasma Cell MyelomaInhibit immunity (T cell function)Targeting CD38 Suppresses Induction and Function of T Regulatory Cells to Mitigate Immunosuppression in Multiple Myeloma.
27418644Plasma cell myelomaInhibit immunity (T cell function)The immune checkpoint molecules programmed death ligand 1 (PD-L1), Galectin-9, herpesvirus entry mediator (HVEM), and CD200, as well as T-cell metabolism regulators indoleamine 2, 3-dioxygenase (IDO), and CD38 are significantly upregulated during osteoclastogenesis.
27418644Plasma cell myelomaInhibit immunityWhen targeted by an anti-CD38 mAb, suppressive T-cell function by OCs is alleviated, associated with downregulation of HVEM and IDO.
Summary
SymbolCD38
NameCD38 molecule
Aliases ADP-ribosyl cyclase 1; CD38 antigen (p45); ADPRC 1; ADPRC1; 2'-phospho-ADP-ribosyl cyclase; 2'-phospho-cycli ......
Chromosomal Location4p15.32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of CD38 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolCD38
NameCD38 molecule
Aliases ADP-ribosyl cyclase 1; CD38 antigen (p45); ADPRC 1; ADPRC1; 2'-phospho-ADP-ribosyl cyclase; 2'-phospho-cycli ......
Chromosomal Location4p15.32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of CD38 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.30.606
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.4170.714
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.8230.369
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.0950.818
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.1610.887
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.0120.993
729033130MelanomaallAnti-PD-1 (nivolumab) 26231.030.117
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15111.5990.143
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.4560.693
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 481.5980.135
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.740.66
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.3160.243
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of CD38 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.71.42.30.469
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.71.720.532
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.707.71
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.16.24.91
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 592011.18.91
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolCD38
NameCD38 molecule
Aliases ADP-ribosyl cyclase 1; CD38 antigen (p45); ADPRC 1; ADPRC1; 2'-phospho-ADP-ribosyl cyclase; 2'-phospho-cycli ......
Chromosomal Location4p15.32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CD38. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolCD38
NameCD38 molecule
Aliases ADP-ribosyl cyclase 1; CD38 antigen (p45); ADPRC 1; ADPRC1; 2'-phospho-ADP-ribosyl cyclase; 2'-phospho-cycli ......
Chromosomal Location4p15.32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CD38. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CD38.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolCD38
NameCD38 molecule
Aliases ADP-ribosyl cyclase 1; CD38 antigen (p45); ADPRC 1; ADPRC1; 2'-phospho-ADP-ribosyl cyclase; 2'-phospho-cycli ......
Chromosomal Location4p15.32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CD38. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolCD38
NameCD38 molecule
Aliases ADP-ribosyl cyclase 1; CD38 antigen (p45); ADPRC 1; ADPRC1; 2'-phospho-ADP-ribosyl cyclase; 2'-phospho-cycli ......
Chromosomal Location4p15.32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of CD38 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolCD38
NameCD38 molecule
Aliases ADP-ribosyl cyclase 1; CD38 antigen (p45); ADPRC 1; ADPRC1; 2'-phospho-ADP-ribosyl cyclase; 2'-phospho-cycli ......
Chromosomal Location4p15.32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between CD38 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolCD38
NameCD38 molecule
Aliases ADP-ribosyl cyclase 1; CD38 antigen (p45); ADPRC 1; ADPRC1; 2'-phospho-ADP-ribosyl cyclase; 2'-phospho-cycli ......
Chromosomal Location4p15.32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting CD38 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting CD38.
ID Name Drug Type Targets #Targets
DB09331DaratumumabBiotechCD381